Literature DB >> 19088161

A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys.

A Juul1, K Sørensen, L Aksglaede, I Garn, E Rajpert-De Meyts, I Hullstein, P Hemmersbach, A M Ottesen.   

Abstract

BACKGROUND: Testosterone (T) is excreted in urine as water-soluble glucuronidated and sulfated conjugates. The ability to glucuronidate T and other steroids depends on a number of different glucuronidases (UGT) of which UGT2B17 is essential. The aim of the study was to evaluate the influence of UGT2B17 genotypes on urinary excretion of androgen metabolites in pubertal boys. STUDY
DESIGN: A clinical study of 116 healthy boys aged 8-19 yr. UGT2B17 genotyping was performed using quantitative PCR. Serum FSH, LH, T, estradiol (E2), and SHBG were analyzed by immunoassays, and urinary levels of androgen metabolites were quantitated by gas chromatography/mass spectrometry in all subjects.
RESULTS: Ten of 116 subjects (9%) presented with a homozygote deletion of the UGT2B17 gene (del/del), whereas 52 and 54 boys were hetero- and homozygous carriers of the UGT2B17 gene (del/ins and ins/ins), respectively. None of the reproductive hormones were affected by UGT2B17 genotype. In all subjects, mean urinary T/epitestosterone ratio was 1.56 [1.14 (SD); 0.1-6.9 (range)] and unaffected by age or pubertal stage. Subjects with homozygous deletions of UGT2B17 had significantly lower urinary levels of T and 5alpha- and 5beta-androstanediol. Mean urinary T/epitestosterone was significantly reduced in del/del subjects [0.29 (0.30); 0.1-1.0 (range), P < 0.0001].
CONCLUSION: In pubertal boys, a common homozygous deletion in the UGT2B17 gene strongly affected urinary excretion pattern of androgen metabolites but did not influence circulating androgen levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19088161     DOI: 10.1210/jc.2008-1984

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Increased number of sex chromosomes affects height in a nonlinear fashion: a study of 305 patients with sex chromosome aneuploidy.

Authors:  Anne Marie Ottesen; Lise Aksglaede; Inger Garn; Nicole Tartaglia; Flora Tassone; Claus H Gravholt; Anders Bojesen; Kaspar Sørensen; Niels Jørgensen; Ewa Rajpert-De Meyts; Tommy Gerdes; Anne-Marie Lind; Susanne Kjaergaard; Anders Juul
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

2.  Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.

Authors:  Ebrahim Eskandari-Nasab; Mohammad Hashemi; Hamzeh Rezaei; Aliakbar Fazaeli; Mohammad Ali Mashhadi; Simin Sargholzaei Moghaddam; Farshid Arbabi; Mahdi Jahantigh; Mohsen Taheri
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

3.  A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk.

Authors:  Chang Sun; Dezheng Huo; Catherine Southard; Barbara Nemesure; Anselm Hennis; M Cristina Leske; Suh-Yuh Wu; David B Witonsky; Olufunmilayo I Olopade; Anna Di Rienzo
Journal:  Hum Genet       Date:  2011-06-10       Impact factor: 4.132

4.  Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.

Authors:  Andy Z X Zhu; Lisa S Cox; Jasjit S Ahluwalia; Caroline C Renner; Dorothy K Hatsukami; Neal L Benowitz; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2015-05       Impact factor: 2.089

5.  Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids.

Authors:  Nawed Deshmukh; Andrea Petróczi; James Barker; Andrea D Székely; Iltaf Hussain; Declan P Naughton
Journal:  Subst Abuse Treat Prev Policy       Date:  2010-04-29

6.  Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers.

Authors:  Shanly M Chen; Daniel H Atchley; Michael A Murphy; Bill J Gurley; Landry K Kamdem
Journal:  J Clin Pharmacol       Date:  2015-12-31       Impact factor: 3.126

7.  Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years.

Authors:  Haeyoung Zhang; Abdul Basit; Chris Wolford; Kuan-Fu Chen; Andrea Gaedigk; Yvonne S Lin; J Steven Leeder; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2020-02-12       Impact factor: 6.875

8.  UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study.

Authors:  Y-H Wang; M Trucksis; J J McElwee; P H Wong; C Maciolek; C D Thompson; T Prueksaritanont; G C Garrett; R Declercq; E Vets; K J Willson; R C Smith; J A Klappenbach; G J Opiteck; J A Tsou; C Gibson; T Laethem; P Panorchan; M Iwamoto; P M Shaw; J A Wagner; J C Harrelson
Journal:  Clin Pharmacol Ther       Date:  2012-06-06       Impact factor: 6.875

9.  Copy number variants in patients with severe oligozoospermia and Sertoli-cell-only syndrome.

Authors:  Frank Tüttelmann; Manuela Simoni; Sabine Kliesch; Susanne Ledig; Bernd Dworniczak; Peter Wieacker; Albrecht Röpke
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Red wine and component flavonoids inhibit UGT2B17 in vitro.

Authors:  Carl Jenkinson; Andrea Petroczi; Declan P Naughton
Journal:  Nutr J       Date:  2012-09-07       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.